GenEdit Is a Phase I Winner of the NIH TARGETED Challenge

SOUTH SAN FRANCISCO, Calif., December 13, 2023 – GenEdit, Inc., a developer of genetic medicines that leverage its NanoGalaxy® platform for tissue-selective delivery, today announced that it is a Phase I winner of the National Institutes of Health (NIH) TARGETED Challenge for programmable delivery systems for gene editing. GenEdit’s application highlighted delivery to the nervous, immune, and other extra-hepatic systems along with possible therapeutic applications.

“The NIH challenge shows the importance of programmable delivery systems for genetic medicines,” said Romu Corbau, Ph.D., Chief Scientific Officer of GenEdit. “The award is a recognition of the potential of the NanoGalaxy platform for a broad range of genetic medicines for multiple therapeutic areas.”

About the TARGETED Challenge
The Targeted Genome Editor Delivery (TARGETED) Challenge is a $6,000,000 challenge to improve the current state of in vivo delivery technologies for genome editors in two Target Areas: 1) Programmable Delivery System for Gene Editing and 2) Crossing the Blood-Brain Barrier. The Challenge is a three-phase competition. In Phase 1, participants were asked to submit a proposal describing their proposed solution and how it addresses the requirements for one of the Target Areas.

About GenEdit
At GenEdit, our mission is to develop innovative genetic medicines with targeted in vivo delivery. Our NanoGalaxy® platform of non-viral, non-lipid hydrophilic nanoparticles (HNPs) offer a combination of advantages over other delivery methods, including tissue selectivity, payload flexibility, low immunogenicity, ability to re-dose, and ease of manufacturing. We are leveraging our platform to develop therapeutics for internal and partnered programs. For more information, visit and follow us on LinkedIn.

Corporate: Kunwoo Lee, Ph.D., GenEdit, Inc.,
Media: Jessica Yingling, Ph.D., Little Dog Communications, +1.858.344.8091